References
- Atlanta: American Cancer Society. Cancer facts & figures; 2018; [cited 2018 Nov 29]. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf
- National Comprehensive Cancer Network. The NCCN guidelines® version 2. Multiple myeloma; 2019; [cited 2018 Nov 29]. Available from: https://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf
- Hagiwara M, Panjabi S, Sharma A, et al. Retrospective study of frequency and cost of multiple myeloma (MM) complications and treatment (Tx) related adverse events (AEs). J Clin Oncol. 2016;34:8060–8060.
- Teitelbaum A, Ba-Mancini A, Huang H, et al. Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data. Oncologist. 2013;18:37–45.
- Arikian SR, Milentijevic D, Binder G, et al. Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma. Curr Med Res Opin. 2015;31:1105–1115.
- MacEwan JP, Batt K, Yin W, et al. Economic burden of multiple myeloma among patients in successive lines of therapy in the United States. Leuk Lymphoma. 2018;59:941–949.
- Pandya S, Clancy Z, Shrestha S, et al. Economic burden of early progression in newly-diagnosed multiple myeloma patients. J Clin Oncol. 2018;36:e20040.
- Clancy Z, Pandya S, Shrestha S, et al. Real-world economic outcomes of early progression in newly diagnosed multiple myeloma (NDMM) patients (Pts). J Clin Oncol. 2018;36:194.
- Bhowmik D, Hines DM, Intorcia M, et al. Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database. J Med Econ. 2018;21:622–628.
- Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34:3661–3679.
- Johnson ES, Bartman BA, Briesacher BA, et al. The incident user design in comparative effectiveness research. Pharmacoepidemiol Drug Saf. 2013;22:1–6.
- Klever M, Wider D, Keller K, et al. Vorinostat (V) in combination with bortezomib (B), doxorubicin (D) and dexamethasone (D) (VBDD) in patients with refractory or relapsed multiple myeloma: an intersim phase I/II analysis. Blood. 2013;122:3202.
- Truven Health Analytics, IBM Watson Health. The Truven Health MarketScan databases for health services researchers; [cited 2019 Jan 23]. Available from: https://truvenhealth.com/portals/0/assets/2017_MarketScan_Databases_Health_Services_Researchers.pdf
- Song X, Cong Z, Wilson K. Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States. Curr Med Res Opin. 2016;32:95–103.
- Lin DY, Feuer EJ, Etzioni R, et al. Estimating medical costs from incomplete follow-up data. Biometrics. 1997;53:419–434.
- Mues KE, Liede A, Liu J, et al. Use of the Medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled populations in the US. Clin Epidemiol. 2017;9:267–277.